Medicine
Lyrica CR 330 mg extended-release tablet
Lyrica CR 330 mg extended-release tablet is a prescription medicine containing Pregabalin for oral use, marketed by Viatris Specialty, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and…
Key facts
- Active ingredient (INN)
- Pregabalin
- Brand
- Lyrica CR
- Strength
- 330 mg
- Dosage form
- Extended-release tablet
- Route
- Oral
- Packs
- 30 tablets
- Marketing authorisation holder
- Viatris Specialty
- Manufacturer
- Viatris Specialty
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (between 59°F and 86°F) in the original package.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Schedule CV
- ATC code
- N02BF02 Pregabalin
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 11 July 2024
- Identifiers
- RxCUI 1988974, 1988977, 1988980 +3DailyMed set ID f280bbd8-2af2-444a-bd96-e409337ca6ddNDC 58151-247Application NDA209501
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 30 tablet, film coated, extended release in 1 bottle | 58151-247-93 | Viatris Specialty | 11 July 2024 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Pregabalin 330 mg extended-release tablet.
Other strengths and forms of Pregabalin
Clinical summary
Pregabalin is a prescription medicine indicated for management of neuropathic pain associated with diabetic peripheral neuropathy, among other approved uses. It is available as capsules, extended-release tablets and oral solution. MedsAcross supplies Pregabalin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about PregabalinFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Lyrica prescribing information (Viatris Specialty) · U.S. National Library of Medicine, DailyMed
- Lyrica: European public assessment report (EPAR) · European Medicines Agency
- Pregabalin Viatris Pharma (previously Pregabalin Pfizer): European public assessment report (EPAR) · European Medicines Agency
Need Lyrica CR 330 mg extended-release tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.